In a recent National Review article, Dr. Michael J. New examines State of Louisiana v. FDA, a case challenging federal policies that allow mifepristone to be prescribed through telehealth and distributed by mail.
The Fifth Circuit Court of Appeals heard oral arguments in the case on September 9.
New discusses the case’s potential implications for state abortion laws, the legal arguments raised by Louisiana and related litigation in other states.
Read Dr. New’s full analysis here.